10-Q: Neuronetics Q2 2026: Revenue Up, But Going Concern Doubt Looms

Neuronetics reported increased revenue in Q2 2026 driven by its Greenbrook segment, but faces substantial doubt regarding its ability to continue as a going concern due to projected covenant non-compliance.

Summary

• Neuronetics reported total revenues of $41.6 million for the three months ended June 30, 2026, an increase of 9% from $38.1 million in the prior year period.
• For the six months ended June 30, 2026, total revenues were $76.0 million, an increase of 8% from $70.1 million in the prior year period.
• The company incurred a net loss of $3.5 million for the three months ended June 30, 2026, compared to a net loss of $9.8 million in the same period last year.
• For the six months ended June 30, 2026, the net loss was $14.2 million, an improvement from $22.5 million in the prior year period.
• As of June 30, 2026, the company had $19.2 million in cash and cash equivalents and an accumulated deficit of $473.2 million.
• Substantial doubt exists about the company's ability to continue as a going concern due to projected non-compliance with a minimum revenue covenant under its credit facility.
• The company's Greenbrook segment continues to be the primary driver of revenue growth, representing 65% of total revenue for Q2 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued operating losses, substantial accumulated deficit, and the explicit statement of substantial doubt about its ability to continue as a going concern, despite revenue growth.

Positives

• Total revenues increased by 9% to $41.6 million for the three months ended June 30, 2026, compared to the prior year period.
• Total revenues increased by 8% to $76.0 million for the six months ended June 30, 2026, compared to the prior year period.
• Gross margin improved to 51.1% for Q2 2026 from 46.6% in Q2 2025, driven by sales of unlocked capital systems and improved revenue cycle management.
• Operating expenses decreased by 12% to $22.7 million for Q2 2026 compared to $25.8 million in Q2 2025.
• Net loss for Q2 2026 was $3.5 million, a significant improvement from $9.8 million in Q2 2025.
• Net loss for the six months ended June 30, 2026 was $14.2 million, an improvement from $22.5 million in the prior year period.
• The company received $2.2 million in Employee Retention Credit (ERC) proceeds during the six months ended June 30, 2026.

Negatives

• The company has an accumulated deficit of $473.2 million as of June 30, 2026.
• The company incurred negative cash flows from operating activities of $10.4 million for the six months ended June 30, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern.
• The company projects trailing twelve-month revenue for the period ended March 31, 2027, to be below the minimum required revenue covenant.
• If the lender calls the credit facility due to covenant non-compliance, the company is not projected to have the liquidity to repay the loan.
• NeuroStar revenue decreased by $0.4 million to $14.7 million for Q2 2026 compared to the prior year period.
• The company paid $1.1 million of ERC proceeds to Madryn Asset Management, LP.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to projected non-compliance with a minimum revenue covenant under its credit facility.
• If the lender calls the credit facility due to covenant non-compliance, the company is not projected to have the liquidity required to meet its requirement to pay off the loan.
• The company's ability to meet its liquidity needs, including future revenue and liquidity covenants, is dependent on growth in existing and acquired product and service lines and the realization of synergies related to its acquisition of Greenbrook.
• The company has incurred operating losses since its inception and anticipates operating losses will continue in the near term.
• The company is subject to certain financial covenants under its credit facility, including a liquidity and quarterly trailing twelve-month minimum revenue covenants.
• The company's ability to achieve or sustain profitable operations is impacted by its history of losses.
• The company relies on the sale and usage of the System to generate revenues.

Future Outlook

The company anticipates operating losses will continue in the near term as it invests in sales and marketing and product development. The company projects trailing twelve-month revenue for the period ended March 31, 2027, to be below the minimum required revenue covenant under its credit facility, raising substantial doubt about its ability to continue as a going concern.

Management Comments

• StockSavvy.ai notes that management's discussion highlights revenue growth driven by the Greenbrook segment and improved gross margins, while also acknowledging the significant going concern risk.
• Management is actively pursuing actions to meet its minimum revenue covenant, including improvements to revenue cycle management, introducing new treatment options, and pursuing new strategies within its NeuroStar business.
• The company's ability to meet liquidity needs is dependent on growth in its product and service lines and the realization of synergies from the Greenbrook acquisition.

Industry Context

StockSavvy.ai observes that Neuronetics operates in the growing mental health technology sector, specifically focusing on Transcranial Magnetic Stimulation (TMS) for conditions like Major Depressive Disorder (MDD). The acquisition of Greenbrook TMS centers positions the company to capture revenue directly from treatment services, complementing its device sales. However, the company's financial performance and going concern issues highlight the capital-intensive nature and competitive pressures within this evolving industry.

Comparison to Industry Standards

• The company's gross margin of 51.1% for Q2 2026 is an improvement, but its ability to achieve profitability remains a key concern, which is common for early-stage medical device and service companies.
• The significant accumulated deficit of $473.2 million is substantial, indicating a long history of investment and operating losses, a pattern seen in many biotech and medical technology firms before achieving scale.
• The explicit mention of substantial doubt about the ability to continue as a going concern is a critical indicator that the company's financial health is precarious, a situation that requires close monitoring and potentially further capital raises or restructuring.
• Competitors in the TMS market include companies like Magstim and Brainsway, though Neuronetics' integrated model with Greenbrook is a differentiating factor.

Management Changes

Legal Proceedings

• The company is subject from time to time to various claims and legal actions arising during the ordinary course of its business.
• Management believes that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on the company's results of operations, financial condition, or cash flows.

Related Party Transactions

• On March 2, 2026, the company entered into an agreement with Madryn Asset Management, LP and its affiliates, pursuant to which it paid $1.1 million of the ERC proceeds to Madryn. Madryn is the company's largest stockholder, and Avinash Amin, M.D., a representative of Madryn, serves on the Board.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional funds by issuing equity securities.
• Creditors may be impacted by the company's projected inability to meet its minimum revenue covenant and the potential for the credit facility to be called.
• Employees may be concerned about the company's going concern status and its impact on job security and future growth.

Next Steps

• The company is implementing actions to meet its minimum revenue covenant, including improvements to revenue cycle management, introducing new treatment options, and pursuing new strategies within its NeuroStar business.
• The company will continue to monitor macroeconomic impacts on its business, results of operations, and financial results.
• The company will continue to invest in sales and marketing and product development activities.
• The company may seek additional equity or debt financing if current liquidity is insufficient.

Key Dates

Recommendation

The explicit statement of substantial doubt about the company's ability to continue as a going concern, coupled with projected covenant non-compliance and continued operating losses, presents a significant risk to investors. While revenue is growing, the immediate financial precariousness outweighs the positive operational trends.

Keywords

Neuronetics, NeuroStar, Greenbrook TMS, Major Depressive Disorder, Transcranial Magnetic Stimulation, Form 10-Q, Quarterly Report, Mental Health